CARIDIANBCT BIOTECHNOLOGIES LL has a total of 24 patent applications. Its first patent ever was published in 2003. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets medical technology, pharmaceuticals and measurement are CALIBER THERAPEUTICS INC, SOCLEAN INC and PURACATH MEDICAL INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 9 | |
#2 | United States | 8 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | China | 1 | |
#5 | Israel | 1 | |
#6 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Medical technology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Optics | |
#5 | Biotechnology | |
#6 | Basic materials chemistry | |
#7 | Machines |
# | Technology | |
---|---|---|
#1 | Syringes | |
#2 | Object sterilising | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds | |
#5 | Preservation of human bodies | |
#6 | Measuring light | |
#7 | Centrifuges | |
#8 | Optical systems | |
#9 | Microorganisms | |
#10 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Hlavinka Dennis J | 16 |
#2 | Goodrich Raymond P | 12 |
#3 | Cussen Terrence M | 6 |
#4 | Reddy Heather L | 4 |
#5 | Mcginnis Daniel T | 3 |
#6 | Hansen Eric T | 3 |
#7 | Mcginnis Daniel Thomas | 2 |
#8 | Goodrich Laura | 2 |
#9 | Belkind Abraham | 2 |
#10 | Platz Matthew S | 1 |
Publication | Filing date | Title |
---|---|---|
WO2010132167A1 | Stable calibration means for apparatus for photo reduction of contaminants in blood | |
WO2009026073A1 | Prevention of transfusion related acute lung injury using riboflavin and light | |
CN101868255A | Whole blood pathogen inactivated | |
EP2175889A1 | Apparatus for photo reduction of contaminants in blood and blood products with calibration means | |
EP1976852A1 | Methods and compositions for the production of high concentration alloxazine solutions | |
US2007098697A1 | Preventing transfusion related complications in a recipient of a blood transfusion | |
US2005282143A1 | Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components |